Piper Sandler Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective lowered by Piper Sandler from $200.00 to $182.00 in a research report report published on Wednesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock.

SRPT has been the topic of a number of other research reports. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright started coverage on Sarepta Therapeutics in a research note on Monday, November 25th. They issued a “sell” rating and a $80.00 price target on the stock. Finally, StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $175.77.

Sarepta Therapeutics Trading Down 3.3 %

Shares of NASDAQ:SRPT opened at $133.34 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The company has a market cap of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81. The stock’s fifty day moving average price is $122.37 and its 200-day moving average price is $131.48.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC grew its position in shares of Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after buying an additional 63,437 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.